Swiss startup AVEA is making waves in the longevity supplement market with its science-based approach to healthy aging, offering products designed to combat signs of aging and support cellular health through evidence-based formulations.
AVEA's Longevity Approach
AVEA's approach to longevity is rooted in a holistic philosophy that combines scientific research with practical supplementation strategies. The company focuses on developing evidence-based products that target cellular health and aim to slow down the aging process at its core[1].
At the heart of AVEA's longevity approach is the concept of enhancing cellular metabolism and optimizing blood sugar levels[1]. This strategy is based on the understanding that maintaining healthy cellular function is crucial for overall longevity and vitality. AVEA's products are designed to support natural collagen production, enhance cellular renewal and defense mechanisms, and balance blood sugar levels[1].
The company emphasizes a personalized approach to longevity, recognizing that individual needs and goals vary. AVEA offers a tailored routine finder that considers factors such as personal goals, lifestyle habits, and existing routines to recommend the most suitable longevity regimen for each customer[1].
AVEA's product line includes supplements that target specific aspects of longevity:
1. NMN (Nicotinamide Mononucleotide) supplements: These aim to boost NAD+ levels in the body, potentially improving energy metabolism and cellular health[4].
2. Collagen boosters: Designed to support joint health, recovery, and maintain youthful skin appearance[1].
3. Antioxidant complexes: Products like the Avea Booster contain potent anti-inflammatory agents such as resveratrol, which may improve insulin sensitivity and cognitive function[4].
The company's scientific approach is bolstered by its team of experts and advisors, including Dr. med. Shirin Hund as a scientific advisor and Simran Rajarai as a scientific writer[2]. This ensures that AVEA's products and recommendations are grounded in current scientific understanding of aging and longevity.
AVEA's longevity philosophy extends beyond supplementation, advocating for a comprehensive lifestyle approach that includes balanced nutrition, regular exercise, stress management, and quality sleep[1]. The company positions its supplements as part of a broader strategy to optimize health and extend the period of life spent in good health, often referred to as "healthspan"[3].
By combining cutting-edge longevity science with accessible supplementation, AVEA aims to empower individuals to take control of their aging process and maintain vitality throughout their lives[2].
Sources: [1] [2] [3] [4] [5] [6]
Science Behind AVEA Products
AVEA's product line is grounded in scientific research focused on cellular health and longevity. The company's approach centers on targeting key biological processes associated with aging, particularly at the cellular level.
One of AVEA's primary focuses is on NAD+ (nicotinamide adenine dinucleotide), a crucial molecule for cellular energy production and DNA repair. As NAD+ levels naturally decline with age, AVEA offers NMN (nicotinamide mononucleotide) supplements designed to boost NAD+ levels in the body[4]. This approach is based on research suggesting that maintaining higher levels of NAD+ may enhance energy metabolism and overall cellular health.
The company's NMN supplement claims to enhance energy metabolism within as little as a month, potentially making users feel more energized and rested[4]. Additionally, AVEA suggests that their NMN supplement mimics the effects of calorie restriction in the body, although the specific mechanism for this is not detailed[4].
AVEA's product line also includes an antioxidant complex called Avea Booster, which contains resveratrol and other anti-inflammatory agents[4]. This supplement is designed to improve insulin sensitivity and support metabolic and cognitive function. The combination of NMN and the antioxidant complex is marketed as a "Vitality Bundle," reflecting the synergistic approach AVEA takes in formulating its products[4].
The scientific rationale behind AVEA's products extends to collagen supplementation. The company offers collagen boosters aimed at supporting joint health, recovery, and maintaining youthful skin appearance[1]. This aligns with research indicating that collagen production decreases with age, contributing to various signs of aging.
AVEA's collaboration with Lanserhof resulted in the development of the Cell Primer, a supplement designed to stimulate autophagy[3]. Autophagy is a cellular process that removes damaged components and recycles cellular material, which is believed to play a crucial role in longevity. Dr. Jan Stritzke, involved in the development of Cell Primer, states that this supplement offers an innovative approach to stimulating autophagy based on the latest medical research[3].
While AVEA's products are based on scientific principles and emerging research in the field of longevity, it's important to note that the long-term effects of these supplements on human aging are still being studied. As Dr. Nichola Conlon, a molecular biologist, points out, while there is evidence suggesting NAD+ supplementation may improve health span, conclusive long-term proof of its ability to reverse or delay aging in humans is still lacking[4].
AVEA's scientific approach is supported by its team of experts, including scientific advisors and researchers[2]. This ensures that their product development is informed by current scientific understanding of aging and longevity. However, as with all nutritional supplements, the effects can vary between individuals, and more research is needed to fully understand the long-term impacts of these interventions on human health and longevity.
Sources: [1] [2] [3] [4] [5] [6]
Collaboration with Lanserhof
AVEA's collaboration with Lanserhof marks a significant partnership in the longevity and healthspan industry. Lanserhof, known for its global healthcare clinics with high standards, has joined forces with AVEA to expand the range of effective supplements available to clinic guests[3].
The cornerstone of this collaboration is the development of the Cell Primer supplement, a joint effort between Dr. Jan Stritzke, the medical founding director of Lanserhof, and Sophie Chabloz, CSO and Cofounder of AVEA[3]. This innovative product is designed to stimulate autophagy, a cellular process crucial for maintaining cellular health and potentially slowing down the biological aging process.
Dr. Stritzke emphasizes that the Cell Primer offers "an innovative approach to stimulating autophagy" based on the latest medical research, positioning it as "a significant step towards sustainable regeneration and prevention"[3]. This aligns with AVEA's focus on evidence-based supplementation targeting cellular health.
The partnership aims to leverage AVEA's expertise in developing science-backed supplements with Lanserhof's established reputation in the healthcare industry. By integrating AVEA's Cell Primer into Lanserhof's over-the-counter offerings, the collaboration seeks to provide clinic guests with access to cutting-edge longevity solutions[3].
This strategic alliance not only enhances AVEA's market presence but also validates its scientific approach to longevity supplementation. The collaboration with a respected healthcare provider like Lanserhof potentially increases consumer trust in AVEA's products and may facilitate broader adoption of longevity-focused supplements.
The partnership between AVEA and Lanserhof represents a convergence of scientific research, product development, and clinical application in the field of longevity, potentially setting a new standard for evidence-based approaches to extending healthspan[3].
Sources: [1] [2] [3] [4] [5] [6]
Funding and Market Expansion
AVEA, the Swiss longevity supplement startup, has successfully secured significant funding to support its growth and expansion in the European market. In June 2022, the company closed a seed financing round of 2.5 million Swiss Francs (approximately €2.43 million)[5][6]. This funding round was led by Maximon, a longevity company builder, and its Longevity Co-Investment Fund[6].
The investment reflects the growing interest in the longevity market, which is estimated to be worth $8 trillion globally[5]. Dr. Tobias Reichmuth, a serial entrepreneur and founding partner of Maximon, emphasized the potential of the longevity field, stating, "The longevity field is the future of healthcare and we believe AVEA will play an important role in the industry"[6].
AVEA plans to utilize this funding to support several key initiatives:
1. Market Expansion: The company aims to accelerate its growth across Switzerland, Germany, Austria, and the UK[5][6].
2. Scientific Research: A portion of the funds will be allocated to power further scientific research in the field of longevity[6].
3. Product Development: AVEA intends to propel the development of innovative longevity-focused supplements[6].
4. Brand Establishment: The funding will help establish AVEA as a leader in the European longevity supplement market[6].
The timing of AVEA's funding success coincides with a growing consumer trend. Caroline Wagner, chairwoman of the Board of AVEA and founding partner of Maximon, noted, "We are at an inflection point where people not only look at supplements to boost health and vitamin levels, but start to actively invest in a longer healthy lifespan"[6]. This shift in consumer behavior positions AVEA favorably to capture the emerging market opportunity.
AVEA's market strategy focuses on leveraging a science-based approach to help customers navigate the overwhelming health and wellness supplement market[6]. By concentrating on ingredients that work synergistically to slow aging at the cellular level, AVEA aims to differentiate itself in a crowded marketplace.
The company's potential for growth has been recognized by industry observers. Sifted, a technology news site, named AVEA as one of 13 longevity startups to watch according to top investors[6]. This recognition, coupled with the substantial funding, positions AVEA for significant expansion in the coming years.
As AVEA continues to grow, it will likely face challenges in scaling its operations across multiple European markets while maintaining its commitment to scientific rigor and product quality. However, with the backing of experienced investors and a clear market strategy, AVEA appears well-positioned to capitalize on the increasing consumer interest in longevity and healthspan optimization.
Member discussion